6-Chloropyridazine-3-carbaldehyde

Catalog No.: 
ACJRPB365
CAS No.: 
303085-53-2
Molecular Formula: 
C5H3ClN2O
Molecular Weight: 
142.54
6-Chloropyridazine-3-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$64.00In stockIn stock
1g95%$158.00In stockIn stock
5g95%$789.00In stockIn stock
25g95%$3061.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Chloropyridazine-3-carbaldehyde
IUPAC Name6-chloropyridazine-3-carbaldehyde
MDL No.MFCD10698041
Molecular FormulaC5H3ClN2O
Molecular Weight142.54
SMILESO=CC1=NN=C(Cl)C=C1
InChI KeyYDHRPQYMQCOQQT-UHFFFAOYSA-N
Synonym6-chloropyridazine-3-carbaldehyde | 303085-53-2 | 6-chloro-3-pyridazinecarboxaldehyde | 3-Chloro-6-formylpyridazine | 6-Chloropyridazine-3-carboxaldehyde | 3-PYRIDAZINECARBOXALDEHYDE, 6-CHLORO- | MFCD10698041 | SCHEMBL1483826 | AMY2197 | DTXSID40624921 | 6-Chloro-3-pyridazin
CAS No.303085-53-2
PubChem CID22336267

Synthetic Route by SureRoute

1. ACJRPB365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNROZ260 route compound structure diagram
    ACNROZ260141-30-0In Stock
  4. Then
  5. ACJRPB365 route product structure diagram
    ACJRPB365303085-53-2In Stock
Inquiry

2. ACJRPB365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTQYG196 route compound structure diagram
    ACTQYG1961011487-94-7In Stock
  2. Then
  3. ACJRPB365 route product structure diagram
    ACJRPB365303085-53-2In Stock
Inquiry

3. ACJRPB365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTDYX265 route compound structure diagram
    ACTDYX265135034-10-5
  4. Then
  5. ACJRPB365 route product structure diagram
    ACJRPB365303085-53-2In Stock
Inquiry

Comments (0)